Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Antibody, In Relapse/ Refractory Multiple Myeloma

Overview

The purpose of this trial is to assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

SparkCures ID 930
Trial Phase Phase 1
Enrollment 80 Patients
Treatments
Trial Sponsors
  • Pfizer
NCT Identifier

NCT03269136

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Patients with relapse/ refractory multiple myeloma
  • Performance Status of 0- 2 (unless due to bone pain)
  • Adequate bone marrow, kidney and liver function

Exclusion Criteria:

  • History of active autoimmune disorders
  • Active and clinically significant bacterial, fungal, or viral infection
  • Major surgery within 4 weeks of study treatment start
  • Radiation therapy within 2 weeks of study treatment start
  • Less than 30 days since last dose of anti CD38 therapy or less than 5 half-lives since last dose of previous systemic therapy.
  • Stem cell transplant (autologous or allogeneic) within 100 days of study treatment start

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.

SparkCures Verified Accurate, up-to-date information. Learn more


Ochsner Medical Center

Jefferson, LA

Ochsner Foundation Clinic

Jefferson, LA

Illinois
Iowa

SparkCures Verified Accurate, up-to-date information. Learn more

Louisiana
Ochsner Medical Center

Jefferson, LA

Ochsner Foundation Clinic

Jefferson, LA

Massachusetts
New York
North Carolina
Tennessee
Texas

Resources

There are no resources, links or videos to display for this clinical trial.